Modality
mRNA
MOA
PD-L1i
Target
PD-L1
Pathway
Neuroinflam
SMA
Development Pipeline
Preclinical
~Aug 2013
→ ~Nov 2014
Phase 1
~Feb 2015
→ ~May 2016
Phase 2
~Aug 2016
→ ~Nov 2017
Phase 3
Feb 2018
→ Nov 2031
Phase 3Current
NCT04994283
1,683 pts·SMA
2018-02→2025-05·Active
NCT08953497
1,532 pts·SMA
2023-02→2031-11·Recruiting
NCT07652322
119 pts·SMA
2022-12→TBD·Not yet recruiting
3,334 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-05-0811mo agoPh3 Readout· SMA
2026-02-221mo agoConference· SMA
2031-11-085.6y awayPh3 Readout· SMA
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Active
P3
Not yet…
P3
Recruit…
Catalysts
Ph3 Readout
2025-05-08 · 11mo ago
SMA
Conference
2026-02-22 · 1mo ago
SMA
Ph3 Readout
2031-11-08 · 5.6y away
SMA
RecruitingActiveNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04994283 | Phase 3 | SMA | Active | 1683 | DAS28 |
| NCT08953497 | Phase 3 | SMA | Recruiting | 1532 | UPDRS |
| NCT07652322 | Phase 3 | SMA | Not yet recr... | 119 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Miriglumide | Alnylam | Phase 3 | CD3 |